Polymorphisms of the CYP2C9 gene and in vivo pharmacodynamic and pharmacokinetic outcomes of warfarin. (A) Time course of changes in warfarin daily dose and INR values during the observation period (7 months) in patients with and without the CYP2C9^*3 mutant allele. (B) Comparisons of warfarin clearance and INR/Cp between the 2 CYP2C9 genotypic groups. Bars represent the mean.